Dobutamine
Heart Failure
Off-Label Use
Shock, Cardiogenic

Dobutamine

Dobutamine is approved by the US Food and Drug Administration (FDA) for short-term use in patients with decreased contractility due to heart failure or cardiac procedures resulting in cardiac decompensation. Despite its ability to improve hemodynamics, dobutamine has not shown positive outcomes for heart failure patients in either the hospital or outpatient setting. In patients experiencing cardiogenic shock, short-term intravenous (IV) inotropic support with dobutamine is administered to sustain systemic blood flow and shield against end-organ damage. This off-label use of dobutamine serves as a transient measure until patients can undergo more definitive treatments such as coronary revascularization, mechanical circulatory support, or heart transplant. This activity highlights the FDA-approved indications, off-label uses, mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of dobutamine pertinent to interprofessional healthcare team members involved in treating patients with cardiac disorders or aiming to attain hemodynamic stability.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.